{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:01:01Z","timestamp":1790780461808,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The University of Sydney","id":[{"id":"https:\/\/ror.org\/0384j8v12","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01698-2","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:46:19Z","timestamp":1790779579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding Pharmacokinetic Variability of Pomalidomide: A Physiologically Based Pharmacokinetic Analysis of Disease-Related Physiology, Ethnicity, Hepatic Impairment, Food Effects, Drug Interactions, and Smoking"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6781-2113","authenticated-orcid":false,"given":"Jeffry","family":"Adiwidjaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-9286","authenticated-orcid":false,"given":"Alan V.","family":"Boddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4674-0242","authenticated-orcid":false,"given":"Andrew J.","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"1698_CR1","unstructured":"Raedler LA. Pomalyst\u00ae (pomalidomide) received a new indication for patients with relapsed and\/or refractory multiple myeloma. Am Health Drug Benefits. 2016;9(Spec Feature):111\u20134."},{"issue":"Pt 3","key":"1698_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117297","volume":"242","author":"O Eladl","year":"2025","unstructured":"Eladl O. Molecular glues and PROTACs in targeted protein degradation: mechanisms, advances, and therapeutic potential. Biochem Pharmacol. 2025;242(Pt 3):117297. https:\/\/doi.org\/10.1016\/j.bcp.2025.117297.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1698_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/2040620713480155","volume":"4","author":"AR McCurdy","year":"2013","unstructured":"McCurdy AR, Lacy MQ. Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. Ther Adv Hematol. 2013;4(3):211\u20136. https:\/\/doi.org\/10.1177\/2040620713480155.","journal-title":"Ther Adv Hematol"},{"key":"1698_CR4","unstructured":"European Medicines Agency. Pomalidomide Celgene assessment report. 2013. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/pomalidomide-celgene-epar-public-assessment-report_en.pdf."},{"issue":"11","key":"1698_CR5","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1021\/acsmedchemlett.1c00475","volume":"12","author":"NR Kong","year":"2021","unstructured":"Kong NR, Liu H, Che J, Jones LH. Physicochemistry of cereblon modulating drugs determines pharmacokinetics and disposition. ACS Med Chem Lett. 2021;12(11):1861\u20135. https:\/\/doi.org\/10.1021\/acsmedchemlett.1c00475.","journal-title":"ACS Med Chem Lett"},{"key":"1698_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16051023","author":"O Nadeem","year":"2024","unstructured":"Nadeem O, Ailawadhi S, Khouri J, Williams L, Catamero D, Maples K, et al. Management of adverse events associated with pomalidomide-based combinations in patients with relapsed\/refractory multiple myeloma. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16051023.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1698_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00280-012-2040-6","volume":"71","author":"M Hoffmann","year":"2013","unstructured":"Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L, et al. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2013;71(2):489\u2013501. https:\/\/doi.org\/10.1007\/s00280-012-2040-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1698_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jcph.384","volume":"55","author":"C Kasserra","year":"2015","unstructured":"Kasserra C, Assaf M, Hoffmann M, Li Y, Liu L, Wang X, et al. Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug\u2013drug interaction potential in vitro and in healthy subjects. J Clin Pharmacol. 2015;55(2):168\u201378. https:\/\/doi.org\/10.1002\/jcph.384.","journal-title":"J Clin Pharmacol"},{"key":"1698_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70253","author":"F Alhurayri","year":"2026","unstructured":"Alhurayri F, Younis IR, Jalal SI, Logan TF, Maniar R, Bray SM, et al. Pharmacokinetic drug\u2013drug interaction potential of oral anticancer drugs. Clin Pharmacol Ther. 2026. https:\/\/doi.org\/10.1002\/cpt.70253.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1698_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1177\/1078155219851550","volume":"26","author":"K Sweiss","year":"2020","unstructured":"Sweiss K, Calip GS, Wirth S, Rondelli D, Patel P. Polypharmacy and potentially inappropriate medication use is highly prevalent in multiple myeloma patients and is improved by a collaborative physician-pharmacist clinic. J Oncol Pharm Pract. 2020;26(3):536\u201342. https:\/\/doi.org\/10.1177\/1078155219851550.","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"1698_CR11","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s40262-013-0089-y","volume":"52","author":"ZE Barter","year":"2013","unstructured":"Barter ZE, Tucker GT, Rowland-Yeo K. Differences in cytochrome P450-mediated pharmacokinetics between Chinese and Caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2013;52(12):1085\u2013100. https:\/\/doi.org\/10.1007\/s40262-013-0089-y.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1698_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/jcph.1602","volume":"60","author":"Y Li","year":"2020","unstructured":"Li Y, Kassir N, Wang X, Palmisano M, Zhou S. Population pharmacokinetics and exposure response analysis of pomalidomide in subjects with relapsed or refractory multiple myeloma from the novel combination treatment of pomalidomide, bortezomib, and low-dose dexamethasone. J Clin Pharmacol. 2020;60(8):1061\u201375. https:\/\/doi.org\/10.1002\/jcph.1602.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1698_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bjh.70239","volume":"208","author":"MR Seefat","year":"2026","unstructured":"Seefat MR, Cucchi DGJ, van Boven L, Durdu-Rayman N, Groen K, Levin MD, et al. Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma. Br J Haematol. 2026;208(1):337\u201342. https:\/\/doi.org\/10.1111\/bjh.70239.","journal-title":"Br J Haematol"},{"issue":"11","key":"1698_CR14","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","volume":"118","author":"MQ Lacy","year":"2011","unstructured":"Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011;118(11):2970\u20135. https:\/\/doi.org\/10.1182\/blood-2011-04-348896.","journal-title":"Blood"},{"issue":"5","key":"1698_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/jcph.455","volume":"55","author":"Y Li","year":"2015","unstructured":"Li Y, Xu Y, Liu L, Wang X, Palmisano M, Zhou S. Population pharmacokinetics of pomalidomide. J Clin Pharmacol. 2015;55(5):563\u201372. https:\/\/doi.org\/10.1002\/jcph.455.","journal-title":"J Clin Pharmacol"},{"key":"1698_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17111413","author":"Y Li","year":"2025","unstructured":"Li Y, Sun H, Zhang Z. The evolution and future directions of PBPK modeling in FDA regulatory review. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/pharmaceutics17111413.","journal-title":"Pharmaceutics"},{"issue":"3","key":"1698_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/cpt.3525","volume":"117","author":"P Paul","year":"2025","unstructured":"Paul P, Colin PJ, Musuamba Tshinanu F, Versantvoort C, Manolis E, Blake K. Current use of physiologically based pharmacokinetic modeling in new medicinal product approvals at EMA. Clin Pharmacol Ther. 2025;117(3):808\u201317. https:\/\/doi.org\/10.1002\/cpt.3525.","journal-title":"Clin Pharmacol Ther"},{"key":"1698_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ejpb.2019.07.014","volume":"142","author":"XJH Pepin","year":"2019","unstructured":"Pepin XJH, Sanderson NJ, Blanazs A, Grover S, Ingallinera TG, Mann JC. Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input. Eur J Pharm Biopharm. 2019;142:421\u201334. https:\/\/doi.org\/10.1016\/j.ejpb.2019.07.014.","journal-title":"Eur J Pharm Biopharm"},{"key":"1698_CR19","unstructured":"United States Food and Drug Administration. Pomalyst\u00ae clinical pharmacology and biopharmaceutics review. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204026Orig1s000ClinPharmR.pdf."},{"issue":"1","key":"1698_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1023\/a:1016062224568","volume":"13","author":"SD Mithani","year":"1996","unstructured":"Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res. 1996;13(1):163\u20137. https:\/\/doi.org\/10.1023\/a:1016062224568.","journal-title":"Pharm Res"},{"issue":"9","key":"1698_CR21","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1023\/a:1018917729477","volume":"10","author":"AT Lu","year":"1993","unstructured":"Lu AT, Frisella ME, Johnson KC. Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm Res. 1993;10(9):1308\u201314. https:\/\/doi.org\/10.1023\/a:1018917729477.","journal-title":"Pharm Res"},{"key":"1698_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/CPAA.S171735","volume":"10","author":"Y Li","year":"2018","unstructured":"Li Y, Liu L, Huang L, Wang X, Hoffmann M, Reyes J, et al. A phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension. Clin Pharmacol. 2018;10:89\u201399. https:\/\/doi.org\/10.2147\/CPAA.S171735.","journal-title":"Clin Pharmacol"},{"issue":"3","key":"1698_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/cpt.967","volume":"104","author":"M Drozdzik","year":"2018","unstructured":"Drozdzik M, Busch D, Lapczuk J, Muller J, Ostrowski M, Kurzawski M, et al. Protein abundance of clinically relevant drug-metabolizing enzymes in the human liver and intestine: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2018;104(3):515\u201324. https:\/\/doi.org\/10.1002\/cpt.967.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1698_CR24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1001\/archinte.1969.00300140040009","volume":"123","author":"WL Kopp","year":"1969","unstructured":"Kopp WL, MacKinney AA Jr, Wasson G. Blood volume and hematocrit value in macroglobulinemia and myeloma. Arch Intern Med. 1969;123(4):394\u20136. https:\/\/doi.org\/10.1001\/archinte.1969.00300140040009.","journal-title":"Arch Intern Med"},{"issue":"3","key":"1698_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","volume":"49","author":"TN Johnson","year":"2010","unstructured":"Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49(3):189\u2013206. https:\/\/doi.org\/10.2165\/11318160-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"1698_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/CPAA.S144606","volume":"9","author":"Y Li","year":"2017","unstructured":"Li Y, Wang X, O\u2019Mara E, Dimopoulos MA, Sonneveld P, Weisel KC, et al. Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function. Clin Pharmacol. 2017;9:133\u201345. https:\/\/doi.org\/10.2147\/CPAA.S144606.","journal-title":"Clin Pharmacol"},{"issue":"1","key":"1698_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00280-021-04365-4","volume":"89","author":"T Ide","year":"2022","unstructured":"Ide T, Osawa M, Sanghavi K, Vezina HE. Population pharmacokinetic and exposure\u2013response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma. Cancer Chemother Pharmacol. 2022;89(1):129\u201340. https:\/\/doi.org\/10.1007\/s00280-021-04365-4.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"1698_CR28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/00498250600683262","volume":"36","author":"S Inoue","year":"2006","unstructured":"Inoue S, Howgate EM, Rowland-Yeo K, Shimada T, Yamazaki H, Tucker GT, et al. Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. Xenobiotica. 2006;36(6):499\u2013513. https:\/\/doi.org\/10.1080\/00498250600683262.","journal-title":"Xenobiotica"},{"issue":"12","key":"1698_CR29","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/lt.20519","volume":"11","author":"TN Johnson","year":"2005","unstructured":"Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 2005;11(12):1481\u201393. https:\/\/doi.org\/10.1002\/lt.20519.","journal-title":"Liver Transpl"},{"issue":"1","key":"1698_CR30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","volume":"270","author":"T Shimada","year":"1994","unstructured":"Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270(1):414\u201323. https:\/\/doi.org\/10.1016\/S0022-3565(25)22379-5.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1698_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s13318-020-00667-9","volume":"46","author":"XX An","year":"2021","unstructured":"An XX, Yu Y, Li GF, Yu G. Abundance and associated variations of cytochrome P450 drug-metabolizing enzymes in the liver of East Asian adults: a meta-analysis. Eur J Drug Metab Pharmacokinet. 2021;46(2):225\u201333. https:\/\/doi.org\/10.1007\/s13318-020-00667-9.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"9","key":"1698_CR32","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1021\/acs.molpharmaceut.1c00462","volume":"18","author":"E El-Khateeb","year":"2021","unstructured":"El-Khateeb E, Achour B, Al-Majdoub ZM, Barber J, Rostami-Hodjegan A. Non-uniformity of changes in drug-metabolizing enzymes and transporters in liver cirrhosis: implications for drug dosage adjustment. Mol Pharm. 2021;18(9):3563\u201377. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00462.","journal-title":"Mol Pharm"},{"issue":"7","key":"1698_CR33","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s40262-019-00737-5","volume":"58","author":"GF Li","year":"2019","unstructured":"Li GF, Zheng QS, Yu Y, Zhong W, Zhou HH, Qiu F, et al. Impact of ethnicity-specific hepatic microsomal scaling factor, liver weight, and cytochrome P450 (CYP) 1A2 content on physiologically based prediction of CYP1A2-mediated pharmacokinetics in young and elderly Chinese adults. Clin Pharmacokinet. 2019;58(7):927\u201341. https:\/\/doi.org\/10.1007\/s40262-019-00737-5.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1698_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0022-3565(25)12826-7","volume":"277","author":"M Bourrie","year":"1996","unstructured":"Bourrie M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther. 1996;277(1):321\u201332. https:\/\/doi.org\/10.1016\/S0022-3565(25)12826-7.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1698_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0090-9556(24)15274-9","volume":"27","author":"MA Gibbs","year":"1999","unstructured":"Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos. 1999;27(2):180\u20137. https:\/\/doi.org\/10.1016\/S0090-9556(24)15274-9.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1698_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0009-9236(01)62844-3","volume":"70","author":"C Yao","year":"2001","unstructured":"Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, et al. Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther. 2001;70(5):415\u201324. https:\/\/doi.org\/10.1016\/S0009-9236(01)62844-3.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1698_CR37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1124\/dmd.31.5.565","volume":"31","author":"C Yao","year":"2003","unstructured":"Yao C, Kunze KL, Trager WF, Kharasch ED, Levy RH. Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug Metab Dispos. 2003;31(5):565\u201371. https:\/\/doi.org\/10.1124\/dmd.31.5.565.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"1698_CR38","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/jcph.1145","volume":"58","author":"Y Li","year":"2018","unstructured":"Li Y, Liu L, Wang X, Zhang C, Reyes J, Hoffmann M, et al. In vivo assessment of the effect of CYP1A2 inhibition and induction on pomalidomide pharmacokinetics in healthy subjects. J Clin Pharmacol. 2018;58(10):1295\u2013304. https:\/\/doi.org\/10.1002\/jcph.1145.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1698_CR39","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00228-011-1189-y","volume":"68","author":"DR Plowchalk","year":"2012","unstructured":"Plowchalk DR, Rowland Yeo K. Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. Eur J Clin Pharmacol. 2012;68(6):951\u201360. https:\/\/doi.org\/10.1007\/s00228-011-1189-y.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1698_CR40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40262-019-00741-9","volume":"58","author":"NA Miller","year":"2019","unstructured":"Miller NA, Reddy MB, Heikkinen AT, Lukacova V, Parrott N. Physiologically based pharmacokinetic modelling for first-in-human predictions: an updated model building strategy illustrated with challenging industry case studies. Clin Pharmacokinet. 2019;58(6):727\u201346. https:\/\/doi.org\/10.1007\/s40262-019-00741-9.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1698_CR41","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40262-026-01655-z","volume":"65","author":"C Jackson","year":"2026","unstructured":"Jackson C, Graves RH, Tran TT, Miller NA. Impact of preclinical verification in physiologically based pharmacokinetic modelling for first-in-human predictions: application of a published model building strategy for five compounds. Clin Pharmacokinet. 2026;65(7):1043\u201359. https:\/\/doi.org\/10.1007\/s40262-026-01655-z.","journal-title":"Clin Pharmacokinet"},{"key":"1698_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/CPAA.S167017","volume":"10","author":"Y Li","year":"2018","unstructured":"Li Y, Wang X, Liu L, Reyes J, Palmisano M, Zhou S. Distribution of pomalidomide into semen of healthy male subjects after multiple doses. Clin Pharmacol. 2018;10:53\u201362. https:\/\/doi.org\/10.2147\/CPAA.S167017.","journal-title":"Clin Pharmacol"},{"issue":"8","key":"1698_CR43","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","volume":"44","author":"ZD Jiang","year":"2000","unstructured":"Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000;44(8):2205\u20136. https:\/\/doi.org\/10.1128\/AAC.44.8.2205-2206.2000.","journal-title":"Antimicrob Agents Chemother"},{"key":"1698_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-363","volume":"10","author":"M Gonzales","year":"2010","unstructured":"Gonzales M, Pepin J, Frost EH, Carrier JC, Sirard S, Fortier LC, et al. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis. 2010;10:363. https:\/\/doi.org\/10.1186\/1471-2334-10-363.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1698_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13318-013-0131-3","volume":"39","author":"V Vozmediano","year":"2014","unstructured":"Vozmediano V, Ortega I, Lukas JC, Gonzalo A, Rodriguez M, Lucero ML. Integration of preclinical and clinical knowledge to predict intravenous PK in human: bilastine case study. Eur J Drug Metab Pharmacokinet. 2014;39(1):33\u201341. https:\/\/doi.org\/10.1007\/s13318-013-0131-3.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"1698_CR46","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cpt.2125","volume":"110","author":"T Heimbach","year":"2021","unstructured":"Heimbach T, Chen Y, Chen J, Dixit V, Parrott N, Peters SA, et al. Physiologically based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2021;110(2):297\u2013310. https:\/\/doi.org\/10.1002\/cpt.2125.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1698_CR47","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1021\/tx500203s","volume":"27","author":"SE Kandel","year":"2014","unstructured":"Kandel SE, Lampe JN. Role of protein-protein interactions in cytochrome P450-mediated drug metabolism and toxicity. Chem Res Toxicol. 2014;27(9):1474\u201386. https:\/\/doi.org\/10.1021\/tx500203s.","journal-title":"Chem Res Toxicol"},{"issue":"2","key":"1698_CR48","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1081\/dmr-46136","volume":"37","author":"M Aguiar","year":"2005","unstructured":"Aguiar M, Masse R, Gibbs BF. Regulation of cytochrome P450 by posttranslational modification. Drug Metab Rev. 2005;37(2):379\u2013404. https:\/\/doi.org\/10.1081\/dmr-46136.","journal-title":"Drug Metab Rev"},{"issue":"3","key":"1698_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70215","volume":"15","author":"ARP Schneider","year":"2026","unstructured":"Schneider ARP, Baier V, Schlender JF, Kuepfer L. Comprehensive pathophysiology repository for PBPK modeling in liver cirrhosis: quantifying continuous disease progression and population variability. CPT Pharmacometr Syst Pharmacol. 2026;15(3):e70215. https:\/\/doi.org\/10.1002\/psp4.70215.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"5","key":"1698_CR50","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1023\/a:1008656930082","volume":"20","author":"RK Verbeeck","year":"1998","unstructured":"Verbeeck RK, Horsmans Y. Effect of hepatic insufficiency on pharmacokinetics and drug dosing. Pharm World Sci. 1998;20(5):183\u201392. https:\/\/doi.org\/10.1023\/a:1008656930082.","journal-title":"Pharm World Sci"},{"issue":"6","key":"1698_CR51","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/cpt.3032","volume":"114","author":"BG Small","year":"2023","unstructured":"Small BG, Hatley O, Jamei M, Gardner I, Johnson TN. Incorporation and performance verification of hepatic portal blood flow shunting in minimal and full PBPK models of liver cirrhosis. Clin Pharmacol Ther. 2023;114(6):1264\u201373. https:\/\/doi.org\/10.1002\/cpt.3032.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1698_CR52","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1021\/acs.molpharmaceut.0c00043","volume":"17","author":"S Arora","year":"2020","unstructured":"Arora S, Pansari A, Kilford P, Jamei M, Gardner I, Turner DB. Biopharmaceutic in vitro in vivo extrapolation (IVIV_E) informed physiologically based pharmacokinetic model of ritonavir Norvir tablet absorption in humans under fasted and fed state conditions. Mol Pharm. 2020;17(7):2329\u201344. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00043.","journal-title":"Mol Pharm"},{"key":"1698_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2024.101032","volume":"59","author":"A Watanabe","year":"2024","unstructured":"Watanabe A, Akazawa T, Fujiu M. Understanding mechanisms of negative food effect for voclosporin using physiologically based pharmacokinetic modeling. Drug Metab Pharmacokinet. 2024;59:101032. https:\/\/doi.org\/10.1016\/j.dmpk.2024.101032.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"1698_CR54","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/cts.13494","volume":"16","author":"R Hermann","year":"2023","unstructured":"Hermann R, Rostami-Hodjegan A, Zhao P, Ragueneau-Majlessi I. Seeing what is behind the smokescreen: a systematic review of methodological aspects of smoking interaction studies over the last three decades and implications for future clinical trials. Clin Transl Sci. 2023;16(5):742\u201358. https:\/\/doi.org\/10.1111\/cts.13494.","journal-title":"Clin Transl Sci"},{"issue":"2","key":"1698_CR55","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.clpt.2004.04.003","volume":"76","author":"MS Faber","year":"2004","unstructured":"Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther. 2004;76(2):178\u201384. https:\/\/doi.org\/10.1016\/j.clpt.2004.04.003.","journal-title":"Clin Pharmacol Ther"},{"key":"1698_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-026-04313-2","author":"AK Lenich","year":"2026","unstructured":"Lenich AK, Kishimoto W, Nakase H, Inui T, Mizuguchi H, Ruez S. Extending a liver-based model to lung and intestine: a comparative study of CYP1A1 and CYP1A2 induction by cigarette smoke in human in vitro models. Arch Toxicol. 2026. https:\/\/doi.org\/10.1007\/s00204-026-04313-2.","journal-title":"Arch Toxicol"},{"key":"1698_CR57","doi-asserted-by":"publisher","unstructured":"Johnson TN, Rowland Yeo K, Rostami-Hodjegan A. Predicting the pharmacokinetics (PK) of theophylline (Theo) and its interaction with fluvoxamine (Fluv) in liver cirrhosis (CIRR). ASCPT Meeting; 2011. Clin Pharmacol Ther. 89(Supplement 1):S50. https:\/\/doi.org\/10.1038\/clpt.2010.332.","DOI":"10.1038\/clpt.2010.332"},{"issue":"1","key":"1698_CR58","doi-asserted-by":"publisher","first-page":"51","DOI":"10.6004\/jadpro.2014.5.1.7","volume":"5","author":"SM Clark","year":"2014","unstructured":"Clark SM, Steinbach A, Clemmons AB. Pomalidomide for the treatment of multiple myeloma. J Adv Pract Oncol. 2014;5(1):51\u20136. https:\/\/doi.org\/10.6004\/jadpro.2014.5.1.7.","journal-title":"J Adv Pract Oncol"},{"key":"1698_CR59","unstructured":"Cancer Institute NSW. Multiple myeloma pomalidomide and dexamethasone oral. eviQ Cancer Treatments Online. 2015; Last reviewed: 13 October 2023. Available from: https:\/\/www.eviq.org.au\/."},{"issue":"7","key":"1698_CR60","doi-asserted-by":"publisher","first-page":"676","DOI":"10.2174\/138920007782109733","volume":"8","author":"J Yang","year":"2007","unstructured":"Yang J, Jamei M, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab. 2007;8(7):676\u201384. https:\/\/doi.org\/10.2174\/138920007782109733.","journal-title":"Curr Drug Metab"},{"key":"1698_CR61","unstructured":"Lukacova V, Parrott NJ, Lave T, Fraczkiewicz G, Bolger MB, Woltosz WS. General approach to calculation of tissue:plasma partition coefficients for physiologically based pharmacokinetic (PBPK) modeling. American Association of Pharmaceutical Scientists (AAPS) Meeting; 2008. https:\/\/www.simulations-plus.com\/assets\/Lukacova-General_Approach_Calc_Tissue_Plasma_Partition_Coefficients_PBPK_Modeling-AAPS-2008-1.pdf."},{"key":"1698_CR62","unstructured":"Lukacova V, Parrott NJ, Lave T, Fraczkiewicz G, Bolger MB, Woltosz WS. Role of fraction unbound in plasma in calculations of tissue:plasma partition coefficients. American Association of Pharmaceutical Scientists (AAPS) Meeting; 2008. https:\/\/www.simulations-plus.com\/assets\/Lukacova-Role_Fraction_Unbound_Plasma_Calculations_Tissue_Plasma_Partition_Coefficients-AAPS-2008-1.pdf."},{"issue":"11","key":"1698_CR63","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/cas.12772","volume":"106","author":"K Matsue","year":"2015","unstructured":"Matsue K, Iwasaki H, Chou T, Tobinai K, Sunami K, Ogawa Y, et al. Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma. Cancer Sci. 2015;106(11):1561\u20137. https:\/\/doi.org\/10.1111\/cas.12772.","journal-title":"Cancer Sci"},{"issue":"3","key":"1698_CR64","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/cpdd.470","volume":"8","author":"Y Li","year":"2019","unstructured":"Li Y, Wang X, Liu L, Zhang C, Gomez D, Reyes J, et al. An open-label, phase 1 study to assess the effects of hepatic impairment on pomalidomide pharmacokinetics. Clin Pharmacol Drug Dev. 2019;8(3):346\u201354. https:\/\/doi.org\/10.1002\/cpdd.470.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"1698_CR65","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s10637-022-01320-9","volume":"41","author":"Z Liu","year":"2023","unstructured":"Liu Z, Xu Z, Gao Z, Ren Q, Chang T, Xue J, et al. Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy Chinese subjects under fasting and fed conditions. Invest New Drugs. 2023;41(1):60\u20139. https:\/\/doi.org\/10.1007\/s10637-022-01320-9.","journal-title":"Invest New Drugs"},{"issue":"11","key":"1698_CR66","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/cpdd.1173","volume":"11","author":"Y Wang","year":"2022","unstructured":"Wang Y, Lin S, Wang Y, Wang Z. Bioequivalence of pomalidomide capsules in fasting and fed states in healthy male volunteers: a randomized, open, single-dose, biperiodic, double-crossover study. Clin Pharmacol Drug Dev. 2022;11(11):1246\u201352. https:\/\/doi.org\/10.1002\/cpdd.1173.","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01698-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01698-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01698-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:46:23Z","timestamp":1790779583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01698-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":66,"alternative-id":["1698"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01698-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"At the time of the study, J.A. is an employee of Simulations Plus, Inc. The other authors have no competing interests to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No new or proprietary data were generated as part of this study. All analyses were conducted using physiologically based pharmacokinetic modelling informed by previously published clinical data. The PBPK model is available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","label":"Data and Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.A. designed the research, performed the simulations, analysed the data, contributed to the interpretation, and drafted the manuscript. A.V.B. and A.J.M. designed the research, contributed to the interpretation, and critically revised the manuscript.","order":6,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}